State Street's passive stake at 4.8% is just below the 5% threshold, suggesting routine index or custody holdings rather than a high-conviction bet. Monitor upcoming 13F filings for any material position changes, and watch for the Q4 2026 sura-vec pivotal data in wet AMD as a potential catalyst.
RGNX drugs
RGNX drug pipeline →- ▲ surabgene lomparvovec 7/10 Phase 3
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned)
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026)
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $7.69entry
- T+1 · 6d ago +10.14%α +8.82% · $8.47
- T+4 · todayOpen
- T+5 · in 3h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corp. filed a new SC 13G disclosing a 4.8% passive stake in REGENXBIO Inc., confirming the position is held in the ordinary course of business with no intent to influence control. The filing follows a prior 13G from JPMorgan Chase (5.3%) and comes five days after REGENXBIO reported Q3 revenue of $9.2M (down 69% YoY) and a narrower-than-expected GAAP net loss of $0.62 per share.
Key Financial Metrics
Key Facts
- State Street Corp. filed a new SC 13G disclosing beneficial ownership of 3,153,366 shares of REGENXBIO common stock.
- The stake represents 4.8% of shares outstanding as of September 30, 2026.
- State Street certifies passive intent under Rule 13d-1(b), with no purpose of changing or influencing control.
- This is a new filing from State Street, not an amendment; a prior State Street SC 13G was filed on May 12, 2026.
- The filing follows a JPMorgan Chase SC 13G on October 13, 2026 disclosing a 5.3% passive stake.
Financial Impact
4.8% passive stake valued at approximately $24M based on $504M market cap
Risk Factors
- Passive 13G filing with no activist intent; no immediate catalyst from this disclosure alone.
- Revenue declined 69% YoY in Q3 2026 due to ZOLGENSMA patent expiration, creating fundamental headwinds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000715 |
| Document: 0000093751-26-000715-index.html | 0000093751-26-000715 |
| Document: 0000093751-26-000715.txt | 0000093751-26-000715 |
Track record
15 reports on RGNX
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers